35 assets in Ependymoma

Therapeutic assets addressing Ependymoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Ependymoma	University of Florida	P2	BB (65)
Olaparib Ependymoma	Fundación de investigación HM	P2	BB (64)
Cyclophosphamide Ependymoma	Theodore S. Johnson	P2	B (60)
Etoposide Ependymoma	Theodore S. Johnson	P2	B (60)
Indoximod Ependymoma	Theodore S. Johnson	P2	B (60)
Palbociclib Ependymoma	National Cancer Institute (NCI)	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Ependymoma	National Cancer Institute (NCI)	P2	B (57)
Tazemetostat Ependymoma	National Cancer Institute (NCI)	P2	B (57)
Vemurafenib Ependymoma	National Cancer Institute (NCI)	P2	CCC (55)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Ependymoma	National Cancer Institute (NCI)	P2	CCC (53)
Celecoxib Ependymoma	Medical University of Vienna	P2	CCC (53)
Cytarabine Ependymoma	Medical University of Vienna	P2	CCC (53)
Ensartinib Ependymoma	National Cancer Institute (NCI)	P2	CCC (53)
Fenofibric Acid Ependymoma	Medical University of Vienna	P2	CCC (53)
Irinotecan Ependymoma	Medical University of Vienna	P2	CCC (53)
Ivosidenib Ependymoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Ependymoma	National Cancer Institute (NCI)	P2	CCC (53)
L-Methionine Ependymoma	St. Jude Children's Research Hospital	P2	CCC (53)
Lomustine Ependymoma	Theodore S. Johnson	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Ependymoma	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Ependymoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Ependymoma	National Cancer Institute (NCI)	P2	CCC (53)
Thalidomide Ependymoma	Medical University of Vienna	P2	CCC (53)
Ulixertinib Ependymoma	National Cancer Institute (NCI)	P2	CCC (53)
Cobolimab Ependymoma	GlaxoSmithKline	P1/2	CC (47)
Dostarlimab Ependymoma	GlaxoSmithKline	P1/2	CC (47)
Oxodotreotide Ependymoma	Fundación de investigación HM	P1/2	CC (47)
Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin Dfp-13318 Ependymoma	National Cancer Institute (NCI)	P1/2	CC (46)
b7-h3-car t cells Ependymoma	St. Jude Children's Research Hospital	P1	CC (43)
Ibrutinib Ependymoma	Theodore S. Johnson	P1	CC (43)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells Ependymoma	City of Hope Medical Center	P1	CC (43)
Onc 206 Ependymoma	Sabine Mueller, MD, PhD	P1	CC (43)
Pembrolizumab Ependymoma	National Cancer Institute (NCI)	P1	CC (43)
Rqnestin Ependymoma	Dana-Farber Cancer Institute	P1	CC (43)
Survaxm Ependymoma	Children's Oncology Group	P1	CC (43)